In 2011, Jiuzhang Biology officially entrusted the Institute of Materia Medica, Chinese Academy of Medical Sciences to conduct research on the anti-tumor efficacy and mechanism of action of CHA for injection: "Study on the Anti-tumor Pharmacodynamics of CHA Used Alone and in Combination with Other Drugs" (Contract No.: JZ2011005-JS). On this basis, the two parties signed the "Strategic Cooperation Agreement on the Research and Development of CHA".